Description: Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Sotigalimab and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Multiple product candidates have been discovered using the APXiMAB platform, one of which is commercially available and the others are in clinical development, either internally by Apexigen or by its licensees.
Home Page: www.apexigen.com
APGN Technical Analysis
75 Shoreway Road
San Carlos,
CA
94070
United States
Phone:
650-931-6236
Officers
| Name | Title |
|---|---|
| Dr. Xiaodong Yang M.D., Ph.D. | Pres, CEO & Director |
| Ms. Amy Wong | Sr. VP of Fin. & Operations |
| Dr. Frank J. Hsu M.D. | Chief Medical Officer |
| Mr. William E. Duke Jr. | Chief Financial Officer |
| Mr. Francis W. Sarena | Chief Operating Officer |
| Dr. Jason Wright Ph.D. | Sr. VP of CMC |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3187 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-22 |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |